Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate

Pharmacogenomics Journal

Volumn 11, Issue 5, 2011, Pages 368-374

  Kiefer, F ^a   Witt, S H ^b   Frank, J ^b   Richter, A ^a   Treutlein, J ^b   Lemenager, T ^a   Nothen M M ^c   Cichon, S ^c   Batra, A ^d   Berner, M ^e   Wodarz, N ^f   Zimmermann, U S ^a,g   Spanagel, R ^b   Wiedemann, K ^h   Smolka, M N ^g   Heinz, A ⁱ   Rietschel, M ^b   Mann, K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

acamprosate; alcohol; atrial natriuretic peptide; GATA4; genetic association study

Indexed keywords

ACAMPROSATE; ATRIAL NATRIURETIC FACTOR; NALTREXONE; PLACEBO; TRANSCRIPTION FACTOR GATA 4;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HETEROZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE TRAIT LOCUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; ALCOHOLS; ATRIAL NATRIURETIC FACTOR; FEMALE; GATA4 TRANSCRIPTION FACTOR; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK; TAURINE;

EID: 80053571614     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.51     Document Type: Article

References (41)

1. Treutlein J, Cichon S, Ridinger M, Wodarz N, Soyka N, Zill P et al. Genome-wide association study of alcohol dependence. Arch Gen Psychiatry 2009; 66: 773-784.
2. Prescott CA, Sullivan PF, Kuo PH, Webb BT, Vittum J, Patterson DG et al. Genome-wide linkage study in the Irish affected sib pair study of alcohol dependence: evidence for a susceptibility region for symptoms of alcohol dependence on chromosome 4. Mol Psychiatry 2006; 11: 603-611.
3. Johnson C, Drgon T, Liu QR, Walther D, Edenberg H, Rice H et al. Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 844-853. (Pubitemid 44905437)
4. Liu QR, Drgon T, Johnson C, Walther D, Hess J, Uhl GR. Addiction molecular genetics: 639 401 SNP whole genome association identifies many 'cell adhesion' genes. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 918-925. (Pubitemid 44905448)
5. McBride K, Nemer M. Regulation of the ANF and BNP promoters by GATA factors: lessons learned for cardiac transcription. Can J Physiol Pharmacol 2001; 79: 673-681. (Pubitemid 32745034)
6. Kovács GL. Natriuretic peptides in alcohol withdrawal: central and peripheral mechanisms. Curr Med Chem 2003; 10: 2559-2576. (Pubitemid 37456026)
7. Kiefer F, Wiedemann K. Neuroendocrine pathways of addictive behaviour. Addict Biol 2004; 9: 205-212. (Pubitemid 39491045)
8. Breitling LP, Dahmen N, Illig T, Rujescu D, Nitz B, Raum E et al. Variants in COMT and spontaneous smoking cessation: retrospective cohort analysis of 925 cessation events. Pharmacogenet Genomics 2009; 19: 657-659.
9. Spanagel R. Alcoholism-a systems approach from molecular physiology to behavior. Physiol Rev 2009; 89: 649-705.
10. Mann K, Kiefer F, Smolka M, Gann H, Wellek S, Heinz A. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin Exp Res 2009; 33: 674-683.
11. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017. (Pubitemid 44794003)
12. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 887-893. (Pubitemid 40563110)
13. Barret JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
14. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, Stephens M et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet 2008; 4: e1000214.
15. Gilad Y, Rifkin SA, Pritchard JK. Revealing the architecture of gene regulation: the promise of eQTL studies. Trends Genet 2008; 24: 408-415.
16. Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AFA, Roskin KM et al. Aligning multiple genomic sequences with the Threaded Blockset Aligner. Genome Res 2004; 14: 708-715. (Pubitemid 38500244)
17. Schluterman MK, Krysiak AE, Kathiriya IS, Abate N, Chandalia M, Srivastava D et al. Screening and biochemical analysis of GATA4 sequence variations identified in patients with congenital heart disease. Am J Med Genet A 2007; 143A: 817-823.
18. Skinner HA, Horner JL. Alcohol Dependence Scale: User's Guide. Addiction Research Foundation: Toronto, Canada, 1984.
19. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urge in abstinent alcoholics. Alcohol Clin Exp Res 1995; 19: 600-606.
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Brit J Addict 1991; 86: 1119-1127.
21. Laux L, Glanzmann P, Schaffner P, Spielberger CD. Das State-Trait-Angstinventar. Beltz: Weinheim, Germany, 1981.
22. Durocher D, Nemer M. Combinatorial interactions regulating cardiac transcription. Dev Genet 1998; 22: 250-262. (Pubitemid 28257601)
23. Tremblay JJ, Viger RS. GATA factors differentially activate multiple gonadal promoters through conserved GATA regulatory elements. Endocrinology 2001; 142: 977-986. (Pubitemid 32202804)
24. Xin M, Davis CA, Molkentin JD, Lien CL, Duncan SA, Richardson JA et al. A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc Natl Acad Sci USA 2006; 103: 11189-11194. (Pubitemid 44156494)
25. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science 1985; 230: 767-770. (Pubitemid 16193965)
26. Quirion R, Dalpe M, Dam TV. Characterization and distribution of receptors for the atrial natriuretic peptides in mammalian brain. Proc Natl Acad Sci USA 1986; 83: 174-178. (Pubitemid 16141636)
27. Antoni FA, Hunter EF, Lowry PJ, Noble JM, Seckl JR. Atriopeptin: an endogenous corticotropin-release inhibiting hormone. Endocrinology 1992; 130: 1753-1755.
28. Kellner M, Wiedemann K, Holsboer F. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci 1992; 50: 1835-1842.
29. Wiedemann K, Jahn H, Kellner M. Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp Clin Endocrinol Diabetes 2000; 108: 5-13. (Pubitemid 30160429)
30. Bhattacharya SK, Chakrabarti A, Sandler M, Glover V. Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsychopharmacology 1996; 15: 199-206. (Pubitemid 26255167)
31. Wiedemann K, Jahn H, Yassouridis A, Kellner M. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry 2001; 58: 371-377. (Pubitemid 32299533)
32. Strohle A, Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 2003; 36: 207-214.
33. Medvedev A, Igosheva N, Crumeyrolle-Arias M, Glover V. Isatin: role in stress and anxiety. Stress 2005; 8: 175-183. (Pubitemid 41545954)
34. Kiefer F, Andersohn F, Jahn H, Wolf K, Raedler TJ, Wiedemann K. Involvement of plasma atrial natriuretic peptide in protracted alcohol withdrawal. Acta Psychiatr Scand 2002; 105: 65-70. (Pubitemid 34158070)
35. Hillemacher T, Frieling H, Luber K, Yazici A, Muschler MA, Lenz B et al. Epigenetic regulation and gene expression of vasopressin and atrial natriuretic peptide in alcohol withdrawal. Psychoneuroendocrinology 2009; 34: 555-560.
36. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-680. (Pubitemid 26269327)
37. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008; 32: 1105-1110.
38. Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism-years of progress. Trends Pharmacol Sci 2008; 29: 109-115.
39. Zalewska-Kaszubska J, Cwiek W, Dyr W, Czarnecka E. Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. Neurosci Lett 2005; 388: 45-48. (Pubitemid 41569368)
40. Kiefer F, Jahn H, Otte C, Nakovics H, Wiedemann K. Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. Neurosci Lett 2006; 404: 103-106. (Pubitemid 44041776)
41. Guillaume P, Gutkowska J, Gianoulakis C. Increased plasma atrial natriuretic peptide after acute injection of alcohol in rats. J Pharmacol Exp Ther 1994; 271: 1656-1665. (Pubitemid 24382683)